Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab

SIMPLE SUMMARY: Programmed death-ligand 1 (PD-L1) expression in tumor tissue is a predictor for the efficacy of immune checkpoint inhibitors. We have previously reported that PD-L1 positive rate on circulating tumor cells (CTCs) in non-small cell lung cancer patients at baseline was correlated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Mio, Koh, Yasuhiro, Teraoka, Shunsuke, Sato, Koichi, Oyanagi, Jun, Hayata, Atsushi, Tokudome, Nahomi, Akamatsu, Hiroaki, Ozawa, Yuichi, Endo, Katsuya, Higuchi, Masayuki, Nakanishi, Masanori, Ueda, Hiroki, Yamamoto, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150706/
https://www.ncbi.nlm.nih.gov/pubmed/34064720
http://dx.doi.org/10.3390/cancers13102290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150706/
https://www.ncbi.nlm.nih.gov/pubmed/34064720
http://dx.doi.org/10.3390/cancers13102290

Ejemplares similares